GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oryzon Genomics SA (STU:ORN) » Definitions » Additional Paid-In Capital

Oryzon Genomics (STU:ORN) Additional Paid-In Capital : €0.00 Mil(As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Oryzon Genomics Additional Paid-In Capital?


Oryzon Genomics's quarterly additional paid-in capital increased from Sep. 2023 (€86.55 Mil) to Dec. 2023 (€93.65 Mil) but then stayed the same from Dec. 2023 (€93.65 Mil) to Mar. 2024 (€0.00 Mil).

Oryzon Genomics's annual additional paid-in capital increased from Dec. 2021 (€74.11 Mil) to Dec. 2022 (€80.67 Mil) and increased from Dec. 2022 (€80.67 Mil) to Dec. 2023 (€93.65 Mil).


Oryzon Genomics Additional Paid-In Capital Historical Data

The historical data trend for Oryzon Genomics's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oryzon Genomics Additional Paid-In Capital Chart

Oryzon Genomics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 80.83 74.78 74.11 80.67 93.65

Oryzon Genomics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 85.47 85.91 86.55 93.65 -

Oryzon Genomics Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Oryzon Genomics Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Oryzon Genomics's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Oryzon Genomics (STU:ORN) Business Description

Traded in Other Exchanges
Address
Sant Ferran 74, Cornellà de Llobregat, Barcelona, ESP, 08940
Oryzon Genomics SA is a clinical stage biopharmaceutical company and engaged in the development of epigenetics-based therapeutics. It is engaged in the field of epigenetic medicine and in the development of therapeutic, biological solutions for cancer and neurodegenerative diseases.